Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.37 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.37 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10365202 | 0.88 | CA2 (0.41) | DAOTSHRTEAD1YAP1TEAD4 | |
| SCHEMBL5848182 | 0.83 | ALDH1A1 (0.48) | TSHRTEAD1YAP1TEAD4TEAD2 | |
| SCHEMBL10743672 | 0.82 | DAO (0.42) | DAOTSHRTEAD1YAP1TEAD4 | |
| SCHEMBL9712031 | 0.82 | CA2 (0.52) | DAOTSHRCA2CA12CA1 | |
| SCHEMBL13652188 | 0.78 | MAOA (0.56) | DAOTSHRCA2CA12CA1 | |
| SCHEMBL15672238 | 0.78 | KIF11 (0.47) | DAOTSHRCA2CA12CA1 | |
| SCHEMBL5974403 | 0.77 | NR1H2 (0.46) | TSHRTEAD1YAP1TEAD4TEAD2 | |
| SCHEMBL20655968 | 0.77 | MAPK1 (0.42) | TSHRTEAD1YAP1TEAD4TEAD2 | |
| SCHEMBL1274257 | 0.75 | TEAD1 (0.53) | TSHRTEAD1YAP1TEAD4TEAD2 | |
| SCHEMBL16591748 | 0.74 | MAOB (0.40) | DAOTSHRCA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-0206662-B1 | THIAZOLIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | Tanabe Seiyaku Co., Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
| US-4777178-A | CARDIOTONIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| US-4689327-A | N-substituted-2-[2-[2-(4-phenylpiperazine-1-yl)ethoxy]phenyl]-thiazolidine-3-carboxamides useful as cardiotonic agent | TANABE SEIYAKU CO., LTD. (JP) | 1987-08-25 | — | — | US | disclosed |
| EP-0206662-A1 | Thiazolidine derivatives and process for preparing the same | Tanabe Seiyaku Co., Ltd. (JP) | 1986-12-30 | — | — | EP | disclosed |
| EP-0167355-A2 | Thiazolidine derivative and processes for preparing the same | Tanabe Seiyaku Co., Ltd. (JP) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | DAO 443/4885TSHR 1420/4885TEAD1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.